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Overexpression of Bcl-2 promotes survival and
differentiation of neuroepithelial stem cells after
transplantation into rat aganglionic colon
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Abstract
Introduction: Neural stem cell transplantation is a promising tool for the restoration of the enteric nervous system
in a variety of motility disorders. However, limited cell viability after transplantation has restricted its regenerative
capacity. The aim of this study was to evaluate the effect of transplantation of neuroepithelial stem cell (NESC)
overexpressing anti-apoptotic gene Bcl-2 on the survival, differentiation and function of grafted cells in rat
aganglionic colon.
Methods: NESCs were isolated from neural tube of embryonic rat (embryonic day 11.5) and manipulated to
overexpress the Bcl-2 gene. After transplantation into the benzalkonium chloride-induced rat aganglionic colon,
grafted cells were visualized in colonic sections. Apoptosis and differentiation of the implanted cells were assessed
1, 4 and 8 weeks post transplantation, respectively. Eight weeks post transplantation, neuronal function of the
colon was assessed by measuring the response of muscle strips to electrical field stimulation.
Results: Transplantation with Bcl-2-NESCs reduced apoptosis within the transplant at 1 week compared with the
vector-NESC grafted group. Our findings also indicated that overexpression of Bcl-2 in the transplanted NESCs
enhanced differentiation into PGP9.5-positive and neuronal nitric oxide synthase-positive neurons at 8-week
assessment. Moreover, electrical field stimulation-induced relaxation of colonic strips was also significantly increased
in the Bcl-2-NESC grafted group.
Conclusion: Transplantation of NESCs genetically modified to overexpress Bcl-2 may have value for enhancing
survival and neurogenesis of grafted cells in the adult gut environment and for improving the efficacy of stem cell
therapy following a broad range of gastrointestinal motility disorders.
Introduction
Gastrointestinal motility disorders such as Hirschsprung’s
disease are characterized by complete or partial loss of
neurons in variable lengths of the enteric nervous system
(ENS) [1]. The treatment of the disorders is far from satis-
factory and remains palliative at best. Theoretically, a real
cure will restore or replace missing or dysfunctional neu-
rons with healthy ones. Advances in molecular and stem
cell biology have provided new avenues for therapy for
ENS disorders and have led to the development of the
ENS stem cell field [2-4]. Several potential sources of cells
capable of generating enteric neurons have been explored
for ENS replenishment in disorders characterized by dys-
functional or absent ENS including central nervous sys-
tem-derived neural stem cells (NSCs), neural crest stem
cells (NCSCs) and ENS progenitor cells [5-7]. During
development, all neurons and glial cells of the ENS arise
from NCSCs that migrate into and along the gut. Indeed,
neuroepithelial stem cells (NESCs) isolated from the mid-
embryonic rodent neural tube can differentiate into
NCSCs. Using enteric neural precursors (that is, NESCs,
NCSCs) therefore has the potential advantage of using cells
of the same lineage as the desired phenotype. Our previous
studies have also shown that transplantation of such
NESCs resulted in the appearance of neuronal nitric oxide
synthase (nNOS) and choline acetyltransferase-expressing
neurons and improvements in colonic motility [8].
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Although promising, post-transplant survival of NSCs
represents a critical limiting factor for successful anatomi-
cal and functional repopulation of the host tissue. Trans-
planted NSCs can die from a variety of causes: physical
injury, immune attack by the host, lack of trophic factors,
or toxic environmental factors (free radicals, cytokines,
and so on). A large portion of this cell death occurs as
apoptosis within the first week after transplantation [9,10].
Augmenting neuronal replacement by enhancing the sur-
vival and maturation of endogenous progenitors is a
potentially useful treatment for gastrointestinal neurode-
generative diseases. An alternative approach might involve
the overexpression of an anti-apoptotic protein such as
Bcl-2. The 26 kDa Bcl-2 anti-apoptotic protein belongs to
the Bcl-2 family of proteins, which was originally found to
be overexpressed in B-cell lymphoma [11]. The protein
serves as a critical regulator of pathways involved in apop-
tosis, acting to inhibit cell death [12]. Increasing evidence
suggests that, in addition to its anti-apoptotic properties,
Bcl-2 has an important function in cell differentiation and
growth. In vivo studies also indicated that Bcl-2 over-
expression enhanced retinal axon regeneration after
optic-tract transaction [13] and increased axonal growth
of transplanted fetal dopaminergic neurons in the rat
striatum [14]. We therefore aimed to determine whether
overexpressing Bcl-2 of the transplanted NESCs in the




All animal procedures were approved by the Guide for
the Care and Use of Laboratory Animals published by
the National Institute of Health (NIH publication No
85-23, revised 1985). Denervation procedure was per-
formed on 12-week-old female Wistar rats. Topical
application of benzalkonium chloride, a cationic surfac-
tant agent, damages nerve elements selectively, leaving
other tissues intact [15]. The enteric plexus of rat colon
was eliminated by serosal application of 0.5% benzalko-
nium chloride (Sigma, St Louis, MO, USA) that has
been successfully employed in our previous work [8].
Isolation and culturing of rat neuroepithelial stem cells
Cell culture reagents were obtained from Invitrogen (Carls-
bad, CA, USA). Briefly, trunk segments of embryonic day
11.5 Wistar rats were isolated in a dish containing cold
Hank’s buffered salt solution. Gentle trituration was
employed to separate neural tubes from the somites. Tubes
were dissociated using a 0.05% trypsin/ethylenediamine
tetraacetic acid solution for 5 minutes at 37°C. After diges-
tion, a cell suspension was obtained and resuspended in
neurobasal medium containing B27, plus 20 ng/ml basic
fibroblast growth factor. Cells were grown as free-floating
clusters (neurospheres). The spheres were maintained at
37°C with 95% air and 5% CO2 and were passaged by
mechanical dissociation every 5 to 7 days.
Genetic modification of neuroepithelial stem cells
pcDNA3.1/GFP, pcDNA3.1/Bcl-2, or pcDNA3.1 (Invitro-
gen) was used for transfection. NESCs at passage 3 were
trypsinized and washed. Approximately 1.5 × 107 cells
were transfected with 10 μg linearized plasmid and 2 μg
circular pKO Select neo (Stratagene, La Jolla, CA, USA).
Briefly, NESCs were suspended in buffer (20 mM HEPES,
137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM
dextrose, pH 7.05) and electroporated in a BioRad Gene
Pulser (0.4 cm gap electrode at 230 V and 960 μF). After
electroporation, cells were plated and cultured. Determi-
nation of transfection efficiency was performed 24 hours
after transfection by fluorescence microscopy (Olympus,
Tokyo, Japan). For each experiment, at least three micro-
scopic visual fields were counted, and the ratios of
GFP-expressing cells to nonfluorescent cells were calcu-
lated. NESCs transfected with pcDNA3.1/Bcl-2 and
pcDNA3.1 were termed Bcl-2-NESC and vector-NESC,
respectively. The Bcl-2 protein expression level was evalu-
ated by western blotting. All experiments and cell number
determinations were performed in triplicate. Cell cultures
for transplantation were checked for viability by trypan
blue assay and viability was always > 90%.
Cell transplantation
Four weeks after the denervation procedure, we performed
cell transplantation. Animals were divided into Bcl-2
(Bcl-2-NESC transplantation) and control (vector-NESC
transplantation) groups. Rats received daily immunosup-
pression with cyclosporine A (15 mg/kg, intraperitoneally;
Novartis Pharmaceuticals, Cambridge, MA, USA) initiated
3 days prior to transplantation. Cells were pre-labeled with
4’,6-diamidino-2-phenylindole (DAPI; Sigma) 1 hour
before transplantation. After washing with PBS, labeled
NESCs suspended in PBS were injected into the dener-
vated colonic wall surgically from the serosa (100 μl; 5 ×
106 viable cells per rat). Cells were slowly injected and the
capillary was fully retracted 5 minutes after injection to
avoid reflux of cells. The sites of injection were labeled
with 6-0 suture. Animals were sacrificed at 1, 4 and
8 weeks post transplantation. Cell apoptosis was examined
at 1 and 4 weeks and cell differentiation was evaluated at
8 weeks. At the end of the observation period, the treated
colons were removed, washed with PBS and snap frozen
in liquid nitrogen. Frozen sections embedded in optimum
cutting temperature medium (12 μm in thickness) were
prepared. An Olympus BX60 microscope (Olympus) was
used to examine the sections and acquire the images. The
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neuronal function was assessed by measuring the
responses of colonic strips in an organ bath in response to
electrical field stimulation (EFS) at 8 weeks.
Western blotting
Western blotting analysis was performed in vitro or 1, 4
and 8 weeks after cell transplantation to measure Bcl-2
protein expression. Cell and colon (longitudinal and cir-
cular muscles with adherent enteric plexus) extracts
were washed three times with PBS and subsequently
were homogenized in ice-cold lysis buffer, containing
2% SDS, 100 μmol proteinase cocktail inhibitor, 1 mmol
phenylmethyl sulfonylfluoride, 1 mmol dithiothreitol,
and 5 mmol ethylenediamine tetraacetic acid in 50
mmol Tris-buffered saline (50 mmol Tris-HCl; pH 7.4).
After centrifugation (5 minutes, 12,500 × g), the super-
nates were diluted in four times concentrated Laemmli
sample buffer. The protein content was determined
(BSA Protein Assay Kit; Pierce, Rockford, IL, USA). For
Bcl-2 analysis, samples (100 μg protein) boiled for
3 minutes were subjected to 10% SDS-PAGE. After elec-
trophoresis, the proteins were transferred to nitrocellu-
lose membranes (Bio-Rad, Hercules, CA, USA). The
blots were incubated in blocking buffer (5% nonfat dry
milk in Tris-buffered saline containing 0.1% Tween 20)
for 1 hour at room temperature and probed overnight
at 4°C with rabbit polyclonal anti-Bcl-2 antibody
(1:1,000; Cell Signaling, Danvers, MA, USA) and rabbit
polyclonal anti-b-actin (1:2,000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) in blocking buffer. After
washing in Tris-buffered saline-Tween 20, the blots
were incubated with horseradish peroxidase-conjugated
goat anti-rabbit IgG antibody (Sigma) at a dilution of
1:5,000 in blocking buffer for 1 hour at room tempera-
ture. The immunoreactive bands were visualized using
enhanced chemiluminescence (ECL kit; Millipore, Biller-
ica, MA, USA). The membranes were exposed to X-ray
films. The intensities of the bands were quantified using
the NIH Image 3.0 software. In all cases, b-actin was
used as an internal standard.
Apoptosis detection in neural grafts
Apoptotic cells in the transplant were identified by
terminal uridine nick end-labeling (TUNEL) using the
ApopTag kit (Oncor Inc., Gaithersburg, MD, USA). Cell
death was quantified by counting the total cells labeled
by DAPI and the percentage of TUNEL-positive cells. A
stereological count of total cells and double-labeled cells
were conducted on every 10th section to avoid repeated
counting of the same cells.
Immunohistochemical assessments
Colonic sections were double labeled with specific antibo-
dies to identify the differentiated phenotype of the grafted
cells. The sections rinsed in PBS were blocked in 10% goat
serum for 30 minutes at room temperature and then incu-
bated with primary antibodies solution at 4°C overnight.
Enteric neurons were identified using polyclonal antibody
against protein gene product 9.5 (PGP9.5, 1:1,000; ABCAM,
Cambridge, UK), nNOS (1:1,000; Sigma) and choline acetyl-
transferase (1:1,000; ABCAM). Enteric glials were identified
using a mAb against glial fibrillary acidic protein (1:1000;
ABCAM). After washing, tissue was incubated for 30
minutes at room temperature with FITC (fluorescein)-
conjugated goat anti-rabbit IgG (1:200; KPL, Gaithersburg,
MD, USA) and TRITC (rhodamine)-conjugated goat anti-
mouse IgG (1:200; KPL) and cover-slipped with a fluores-
cence mounting medium (Sigma). Primary antibody
omission as well as primary antibodies preincubated with
an excess of blocking peptides (ABCAM) served as negative
controls, and no immunoreactivity was observed.
Organ bath physiology
Animals were killed by cervical dislocation and the treated
colons were removed and placed in Krebs buffer. The
mucosa was removed and circular muscle strips (10 ×
3 mm) were mounted between two L-shaped tissue hooks
in 5 ml chambers containing Krebs buffer at 37°C and con-
tinuously bubbled with 95% O2/5% CO2. Tension was
monitored with an isometric force transducer and recorded
by a digital recording system (JH-2B; Instrument Company
of Chengdu, Chengdu, China). Strips were stretched to 1 g
(5 mN) and allowed to equilibrate for 30 minutes. The
reactions were obtained by application of EFS (90 V, 5 to
40 Hz, 1 ms pulse for a duration of 5 minutes) in the
absence or presence of tetrodotoxin (1 μmol/l; Sigma).
Comparisons among the groups (normal, denervation,
control and Bcl-2) were performed by measuring the area
under the curve of the EFS-induced reactions (AUCR) for
5 minutes and the baseline prior to the EFS for 5 minutes





Mean values were reported together with the standard
error of mean. Student’s two-tailed t test was used for com-
parison of two experimental groups. Multiple comparisons
were done using one-way analysis of variance followed by
the Tukey test for multiple pairwise examinations. Changes
were identified as significant if P < 0.05.
Results
Overexpression of Bcl-2 in genetically modified NESCs
and grafts
The transfection efficiency for genetically modified NESCs
was evaluated by pcDNA3.1/GFP as an internal control
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after 24-hour gene delivery. A representative GFP expres-
sion is shown in Figure 1. More than 85% of NESCs were
transfected based on calculation analysis. NESCs overex-
pressing Bcl-2 contained higher levels of Bcl-2 protein
than that in vector-NESC (Figure 2A, C). Western blotting
showed elevated levels of Bcl-2 protein in the colons
received Bcl-2-NESCs from 1 to 8 weeks after cell trans-
plantation (Figure 2B, D).
Bcl-2 overexpression decreased cell apoptosis in grafts
To assess whether overexpression of Bcl-2 could play a
role in preventing apoptosis in NESC, we performed
Figure 1 Transfection of neuroepithelial stem cells with nonviral vector. (A) to (C) Representative photomicrograph of neuroepithelial stem
cells transfected with pcDNA3.1/GFP 24 hours after transfection. GFP-positive cells are shown in green. Scale bar = 150 μm.
Figure 2 Bcl-2 overexpression in cultured and transplanted cells. (A) Significantly high expression of Bcl-2 was observed in cell cultures
overexpressing the Bcl-2 gene 24 hours after transfection. In contrast, a weak expression of Bcl-2 was detected in vector-NESC. (B) In animal
studies, 1 week after transplantation, a higher level Bcl-2 expression was seen in the transplanted colonic tissues from the Bcl-2 group compared
with that from the control group. The Bcl-2 level remained high for up to 8 weeks after transplantation. (C), (D) Bar graphs showing the Bcl-2
levels in cultures and in cell grafted colons. At different days after transplantation, significantly higher Bcl-2 expression was seen in the colons of
rats receiving Bcl-2-NESC than those receiving vector-NESC. *Significant difference compared with vector-NESC or control group (P < 0.05, n = 6
for cell culture experiments and n = 6 for animal studies). NESC, neuroepithelial stem cell.
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TUNEL staining of colonic sections 1 and 4 weeks post
grafting. Apoptotic cells were significantly reduced in
the NESC grafts that were transfected with Bcl-2 when
compared with the control group at 1-week assessment
(18.8 ± 1.5% and 7.4 ± 0.6% TUNEL-positive cells
for control and Bcl-2 groups, respectively, P < 0.05;
Figure 3). Few TUNEL-positive cells were detected
4 weeks post transplantation and no differences were
found between the groups (data not shown).
Bcl-2 enhanced neuronal differentiation of NESC
transplants
We next examined the possibility that Bcl-2 overexpres-
sion not only reduced cell death but also increased the
neuronal differentiation. Eight weeks after transplantation,
many transplanted cells were immunopositive for the neu-
ronal marker PGP9.5. In addition to differentiating into
neuron-like cells positive for PGP9.5, some transplanted
cells in the colon stained positively for the enteric glia
marker glial fibrillary acidic protein (Figure 4A, B). These
markers co-localized with pre-labeled DAPI, confirming
their transplant origin. Counted on the colonic sections of
the control group at 8 weeks after transplantation, 29.1 ±
1.0% of transplanted vector-NESCs were PGP9.5-positive
whereas 50.7 ± 1.8% of transplanted Bcl-2-NESCs
were PGP9.5-positive (different at P < 0.05; Figure 4C).
Furthermore, nNOS and choline acetyltransferase immu-
noreactivity was observed in host colon within trans-
planted NESCs (Figure 5A, B). Approximately 36.3 ± 1.3%
of DAPI-positive NESCs expressed nNOS in the Bcl-2
group, a proportion apparently higher than that in the
control group (21.4 ± 1.4%) (P < 0.05; Figure 5C).
Bcl-2-engineered NESC transplantation improves
relaxation of the colon
EFS of ex vivo preparations of the colon was performed
to assess neurally mediated reactions of the muscle. As
shown in Figure 6A, there was no reaction to EFS in
denervated colon. In contrast, application of EFS resulted
in a relaxation at lower than 20 Hz and a contraction at
40 Hz in colons of the normal, control and Bcl-2 groups.
This effect was completely blocked by tetrodotoxin, con-
firming its neural origin. EFS-induced relaxation at three
stimulating frequencies lower than 20 Hz was signifi-
cantly increased in colonic muscle strips isolated from
rats receiving Bcl-2-NESCs as compared with control
groups according to the analysis of the value R. Signifi-
cant differences between the control and Bcl-2 groups at
Figure 3 Bcl-2 overexpression decreases cell death. Representative pictures of neuroepithelial stem cell (NESC) grafts in cross-sections of rat colon
in the (A) control group and (B) Bcl-2 group at 1 week post transplantation. 4’,6-Diamidino-2-phenylindole-positive NESCs are shown in blue. Terminal
uridine nick end-labeling (TUNEL) immunoreactivity is indicated in green. Transplanted NESCs that are TUNEL-positive are indicated by arrows. LM,
longitudinal muscle; CM, circular muscle. Scale bar = 200 μm. (C) Quantitative analysis of the number of grafted NESCs that are TUNEL-positive in two
groups. Data expressed as mean ± standard error of the mean; n = 6 for each group; *P < 0.05 versus control group.
Liu et al. Stem Cell Research & Therapy 2013, 4:7
http://stemcellres.com/content/4/1/7
Page 5 of 10
stimulation frequencies of 5, 10 and 20 Hz are shown in
Figure 6B (P = 0.004, P = 0.025 and P = 0.038, respec-
tively). There was also a difference between the normal
and Bcl-2 groups in EFS-induced relaxation merely at 10
Hz stimulation (P = 0.025). In addition, no significant dif-
ference of EFS-induced contraction in 40 Hz was found
among normal, control and Bcl-2 groups.
Discussion
Despite encouraging initial results of NSC replacement as
a therapy for gastroenterology neurodegenerative diseases
reported by many investigators, there are still significant
limitations that prevent the clinical development of this
therapy, including adequate survival, appropriate differen-
tiation and physiological integration into the host tissue.
Adequate survival of grafted cells is a problem of critical
importance that will need to be addressed. Indeed, more
than 90% of the grafted neurons usually die upon grafting,
both in animal and human studies [16,17], and a large
portion of this cell death occurs as apoptosis [9,10].
Adjunct measures to address this issue are therefore essen-
tial. Micci and colleagues reported only a very small pro-
portion of transplanted central nervous system-derived
NSCs actually could be found days to weeks after implan-
tation for the restoration of the ENS. Using a selective inhi-
bitor of caspase-1 (Ac-YVAD-cmk) at the time of central
nervous system-derived NSC transplantation resulted in a
significant improvement in graft survival 1 week post trans-
plantation, but the number of grafted cells was drastically
reduced at 2 and 4 weeks post transplantation [18]. This
finding might suggest that the pharmacological treatment
with a caspase inhibitor might not be sufficient in produ-
cing a long-lasting effect on graft survival. The present
study therefore provided the first evidence that Bcl-2 over-
expression by gene transfer reduced apoptosis of grafted
cells in aganglionic colon of rat, enhanced differentiation
into enteric neurons, and produced a further increase in
functional benefits. In spite of the notion that Bcl-2 may
Figure 4 Bcl-2 overexpression enhances the differentiation to PGP9.5-positive neurons of transplanted cells. Representative pictures of
the (A) control group and (B) Bcl-2 group in cross-sections of colon 8 weeks post transplantation. Grafted neuroepithelial stem cells are shown
in blue. Protein gene product 9.5 (PGP9.5) immunoreactivity is indicated in green. Glial fibrillary acidic protein immunoreactivity is indicated in
red. LM, longitudinal muscle; CM, circular muscle. Scale bar = 200 μm. (C) Ratio of PGP9.5-positive cells versus 4’,6-diamidino-2-phenylindole
(DAPI)-labeled cells was counted. Bcl-2 overexpression increased the ratio of PGP9.5-positive cells. *Significant difference compared with control
group (P < 0.05, n = 6 for each group).
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represent a prototype for a new class of oncogenes [19] and
overexpression of Bcl-2 is common in many types of
human cancer [20], no tumors were seen in our study, per-
haps reflecting the fact that the Bcl-2 overexpression did
not completely prevent apoptosis in the host.
Many factors can contribute to post-transplant cell
death, including necrosis, insufficient growth factor sup-
port, humoral and cellular immunity and programmed cell
death, or apoptosis [21]. Immature cells are particularly
vulnerable to apoptosis [22-25] and transplanted cells may
die in large numbers. This death after transplantation can
be an additional burden to the gut already compromised
by a cellular debris load [26,27]. Our present studies
revealed that genetic modification of NESCs with Bcl-2
effectively protected transplanted NESCs against apoptosis
and increased cell survival 1 week after implantation.
There were no drastic reductions in numbers of grafted
cells at long-term assessment, possibly due to the fact that
elevated Bcl-2 levels lasted from 1 to 8 weeks after cell
transplantation.
The anti-apoptotic role of Bcl-2 has been well estab-
lished in previous studies dealing with the differentiation
of neural progenitors, and NSCs, in general [28,29]. Con-
sistent with the idea that anti-apoptotic gene modifications
may have beneficial effects on neural differentiation, Lee
and colleagues reported that enhancing graft survival with
the anti-apoptotic gene Bcl-X(L) could potentiate thera-
peutic benefits of NSC-based therapy for spinal cord injury
[30]. After transplantation into the aged rat striatum, Bcl-
X(L)-overexpressing hNS1 cells generated more neurons
and less glia than the control ones, confirming the results
obtained in vitro, which indicated an action of Bcl-X(L)
modulating human NSC differentiation [31]. Our data also
indicated that Bcl-2 overexpression in the transplanted
NESCs resulted in promoting neuronal differentiation. We
believed that the higher PGP9.5/DAPI ratio of NESCs
with Bcl-2 overexpression was probably due to an
increased neuronal differentiation from the transplanted
cells.
We have also reported here that Bcl-2-engineered
NESC transplantation in the aganglionic colonic region
significantly improved EFS-induced relaxation compared
with vector-NESCs. This effect most probably resulted
from the restoration of neurally mediated relaxation by
more differentiated neurons secreting important inhibi-
tory enteric neurotransmitter in the Bcl-2 group, which
was certified by immunohistochemistry analysis. Our
results suggested that overexpression of Bcl-2 might
selectively enhance the differentiation into nNOS-posi-
tive inhibitory enteric neurons of grafted cells. The
Figure 5 Neuroepithelial stem cells offer enteric nervous system appropriate differentiation upon grafting into recipient aganglionic
gut. Evidence of 4’,6-diamidino-2-phenylindole (DAPI)-labeled neuroepithelial stem cell graft (shown in blue) differentiation into neuronal nitric
oxide synthase (nNOS; shown in green) and choline acetyltransferase (shown in red) neuronal subtypes was apparent at 8 weeks post
transplantation in the (A) control group and (B) Bcl-2 group. LM, longitudinal muscle; CM, circular muscle. Scale bar = 200 μm. (C) Ratio of
nNOS-positive cells versus DAPI-labeled cells was counted. Bcl-2 overexpression increased the ratio of nNOS-positive cells. *Significant difference
compared with control group (P < 0.05, n = 6 for each group).
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finding that overexpression of Bcl-2 enhanced both the
survival of transplanted cells and functional recovery
supports the idea that the survival is therapeutically
important to achieve, and further specifically indicates
the value of apoptosis reduction through genetic
manipulation.
In any case, the present study suggests that NESCs over-
expressing Bcl-2 may be particularly useful for reducing
apoptotic cell death, promoting neuronal differentiation
and tissue functional recovery. Transplantation of gene-
engineered NESCs may provide a novel and effective
approach in the treatment of disorders of the ENS. How-
ever, further investigation will be needed to determine the
possible mechanisms of differentiation and functional
benefits of Bcl-2 expression in the transplanted cells.
Moreover, the efficacy of the use of gene-modified cells
and/or specific growth factors on the survival of NESC
grafts also will be needed to be explored.
Figure 6 Bcl-2 engineered neuroepithelial stem cell transplantation results in increased relaxation of the colonic muscle .
(A) Representative recordings showed the responses of the colonic circular muscle to electrical field stimulation (EFS) before and after
incubation with 1 μmol/l tetrodotoxin (TTX) in four groups. ↓Marker of EFS (10 Hz) treatment. (B) Quantification of the value R at different
frequencies in four groups. *Significantly different from normal, control and Bcl-2 groups. #Significantly different from control group.
##Significantly different from Bcl-2 group with P < 0.05 (n = 8 for each group). NESC, neuroepithelial stem cell.
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Conclusion
In summary, we have confirmed that genetic modification
with the anti-apoptotic Bcl-2 gene ameliorated cell survival
and improved neuronal differentiation and function of
grafted NESCs in aganglionic colon. Genetically engineer-
ing cells by Bcl-2 using a nonviral vector could be an effec-
tive strategy for increasing cell survival after cell
transplantation. Transplantation of gene-engineered
NESCs may provide a novel and effective approach in the
treatment of disorders of the ENS.
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